Chevy Chase Trust Holdings LLC Has $70.93 Million Position in Gilead Sciences, Inc. $GILD

Chevy Chase Trust Holdings LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 638,962 shares of the biopharmaceutical company’s stock after selling 23,841 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.05% of Gilead Sciences worth $70,925,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new stake in Gilead Sciences during the second quarter worth $2,150,268,000. Ameriprise Financial Inc. increased its stake in shares of Gilead Sciences by 397.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after purchasing an additional 5,392,191 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock worth $1,499,098,000 after buying an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after buying an additional 2,169,266 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after buying an additional 1,893,401 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst optimism — Jefferies and other firms have initiated or reiterated positive coverage, highlighting Gilead’s strong HIV franchise, expanding oncology/cell therapy pipeline and long IP runway (through ~2036), which supports both income and growth narratives. How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story
• Positive Sentiment: Zacks raised near-term EPS estimates (Q1/Q2 and FY2027 upgrades reported), nudging earnings expectations higher — a constructive signal for investors focused on fundamentals. The Zacks Analyst Blog: Oracle, T‑Mobile, Gilead and C&F Financial
• Positive Sentiment: Unusually large call-option activity (130k+ calls) signals bullish positioning by traders, which can amplify upside if catalysts continue. (Market data)
• Positive Sentiment: Index and institutional flows — rising institutional focus amid Nasdaq‑100 dynamics can support demand for GILD shares from passive and quant funds. Gilead (NASDAQ:GILD) Institutional Focus Rises In Nasdaq 100 Index
• Neutral Sentiment: Acquisition rationale — coverage and analyst pieces discuss whether the ~$7.8B Arcellx buy strengthens Gilead’s cell‑therapy franchise amid declining cell therapy sales; the strategic case is positive but clinical/commercial risks remain. Will GILD’s Move to Acquire ACLX Boost Its Cell Therapy Franchise?
• Neutral Sentiment: Market context — broader investor flows into growth/tech vs. traditional defensives are affecting healthcare sector moves; this macro backdrop is neither uniquely positive nor negative for Gilead. Why Investors Aren’t Fleeing to Safe‑Haven Stocks
• Negative Sentiment: Deal/legal risk — a law firm (Kahn Swick & Foti) is investigating Arcellx’s proposed sale to Gilead, citing concerns over price/process; shareholder litigation or regulatory scrutiny could delay or alter the transaction terms and is a near‑term overhang. Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.

Insider Activity

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the sale, the chief executive officer directly owned 566,698 shares in the company, valued at $76,504,230. This represents a 16.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the transaction, the insider directly owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This represents a 18.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 309,280 shares of company stock worth $43,935,470 in the last 90 days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Trading Down 0.2%

NASDAQ GILD opened at $144.99 on Friday. The firm has a market capitalization of $179.99 billion, a PE ratio of 21.42, a price-to-earnings-growth ratio of 1.90 and a beta of 0.37. The business’s 50-day moving average price is $140.62 and its two-hundred day moving average price is $126.87. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.3%. The ex-dividend date is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio (DPR) is 46.68%.

Analyst Ratings Changes

Several analysts recently weighed in on the company. The Goldman Sachs Group raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Scotiabank increased their target price on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Finally, Oppenheimer upped their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.62.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.